Cargando…
Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells
Gemcitabine is a chemotherapeutic agent for pancreatic cancer treatment. It has also been demonstrated to inhibit human pancreatic cancer cell lines, MIA PaCa-2 and PANC-1. The aim of the present study was to investigate the suppressive effect of fucoxanthin, a marine carotenoid, in combination with...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265583/ https://www.ncbi.nlm.nih.gov/pubmed/37324167 http://dx.doi.org/10.3892/br.2023.1629 |
_version_ | 1785058563602776064 |
---|---|
author | Lu, Jun Wu, Xiaowu Jenifer Hassouna, Amira Wang, Kelvin Sheng Li, Yan Feng, Tao Zhao, Yu Jin, Minfeng Zhang, Baohong Ying, Tianlei Li, Jinyao Cheng, Lufeng Liu, Johnson Huang, Yue |
author_facet | Lu, Jun Wu, Xiaowu Jenifer Hassouna, Amira Wang, Kelvin Sheng Li, Yan Feng, Tao Zhao, Yu Jin, Minfeng Zhang, Baohong Ying, Tianlei Li, Jinyao Cheng, Lufeng Liu, Johnson Huang, Yue |
author_sort | Lu, Jun |
collection | PubMed |
description | Gemcitabine is a chemotherapeutic agent for pancreatic cancer treatment. It has also been demonstrated to inhibit human pancreatic cancer cell lines, MIA PaCa-2 and PANC-1. The aim of the present study was to investigate the suppressive effect of fucoxanthin, a marine carotenoid, in combination with gemcitabine on pancreatic cancer cells. MTT assays and cell cycle analysis using flow cytometry were performed to study the mechanism of action. The results revealed that combining a low dose of fucoxanthin with gemcitabine enhanced the cell viability of human embryonic kidney cells, 293, while a high dose of fucoxanthin enhanced the inhibitory effect of gemcitabine on the cell viability of this cell line. In addition, the enhanced effect of fucoxanthin on the inhibitory effect of gemcitabine on PANC-1 cells was significant (P<0.01). Fucoxanthin combined with gemcitabine also exerted significant enhancement of the anti-proliferation effect in MIA PaCa-2 cells in a concentration dependent manner (P<0.05), compared with gemcitabine treatment alone. In conclusion, fucoxanthin improved the cytotoxicity of gemcitabine on human pancreatic cancer cells at concentrations that were not cytotoxic to non-cancer cells. Thus, fucoxanthin has the potential to be used as an adjunct in pancreatic cancer treatment. |
format | Online Article Text |
id | pubmed-10265583 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-102655832023-06-15 Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells Lu, Jun Wu, Xiaowu Jenifer Hassouna, Amira Wang, Kelvin Sheng Li, Yan Feng, Tao Zhao, Yu Jin, Minfeng Zhang, Baohong Ying, Tianlei Li, Jinyao Cheng, Lufeng Liu, Johnson Huang, Yue Biomed Rep Articles Gemcitabine is a chemotherapeutic agent for pancreatic cancer treatment. It has also been demonstrated to inhibit human pancreatic cancer cell lines, MIA PaCa-2 and PANC-1. The aim of the present study was to investigate the suppressive effect of fucoxanthin, a marine carotenoid, in combination with gemcitabine on pancreatic cancer cells. MTT assays and cell cycle analysis using flow cytometry were performed to study the mechanism of action. The results revealed that combining a low dose of fucoxanthin with gemcitabine enhanced the cell viability of human embryonic kidney cells, 293, while a high dose of fucoxanthin enhanced the inhibitory effect of gemcitabine on the cell viability of this cell line. In addition, the enhanced effect of fucoxanthin on the inhibitory effect of gemcitabine on PANC-1 cells was significant (P<0.01). Fucoxanthin combined with gemcitabine also exerted significant enhancement of the anti-proliferation effect in MIA PaCa-2 cells in a concentration dependent manner (P<0.05), compared with gemcitabine treatment alone. In conclusion, fucoxanthin improved the cytotoxicity of gemcitabine on human pancreatic cancer cells at concentrations that were not cytotoxic to non-cancer cells. Thus, fucoxanthin has the potential to be used as an adjunct in pancreatic cancer treatment. D.A. Spandidos 2023-06-01 /pmc/articles/PMC10265583/ /pubmed/37324167 http://dx.doi.org/10.3892/br.2023.1629 Text en Copyright: © Lu et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Lu, Jun Wu, Xiaowu Jenifer Hassouna, Amira Wang, Kelvin Sheng Li, Yan Feng, Tao Zhao, Yu Jin, Minfeng Zhang, Baohong Ying, Tianlei Li, Jinyao Cheng, Lufeng Liu, Johnson Huang, Yue Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells |
title | Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells |
title_full | Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells |
title_fullStr | Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells |
title_full_unstemmed | Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells |
title_short | Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells |
title_sort | gemcitabine‑fucoxanthin combination in human pancreatic cancer cells |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265583/ https://www.ncbi.nlm.nih.gov/pubmed/37324167 http://dx.doi.org/10.3892/br.2023.1629 |
work_keys_str_mv | AT lujun gemcitabinefucoxanthincombinationinhumanpancreaticcancercells AT wuxiaowujenifer gemcitabinefucoxanthincombinationinhumanpancreaticcancercells AT hassounaamira gemcitabinefucoxanthincombinationinhumanpancreaticcancercells AT wangkelvinsheng gemcitabinefucoxanthincombinationinhumanpancreaticcancercells AT liyan gemcitabinefucoxanthincombinationinhumanpancreaticcancercells AT fengtao gemcitabinefucoxanthincombinationinhumanpancreaticcancercells AT zhaoyu gemcitabinefucoxanthincombinationinhumanpancreaticcancercells AT jinminfeng gemcitabinefucoxanthincombinationinhumanpancreaticcancercells AT zhangbaohong gemcitabinefucoxanthincombinationinhumanpancreaticcancercells AT yingtianlei gemcitabinefucoxanthincombinationinhumanpancreaticcancercells AT lijinyao gemcitabinefucoxanthincombinationinhumanpancreaticcancercells AT chenglufeng gemcitabinefucoxanthincombinationinhumanpancreaticcancercells AT liujohnson gemcitabinefucoxanthincombinationinhumanpancreaticcancercells AT huangyue gemcitabinefucoxanthincombinationinhumanpancreaticcancercells |